CONCLUSIONS: When observing long-term follow-up, IBT is associated with a significantly increased risk of both CSM and OM after nephrectomy. Further investigations are needed to fully understand the impact of blood transfusions on RCC and the pathological mechanisms which can be modified by adequate intraoperative and post-operative patient management.
INTRODUCTION AND OBJECTIVES: The role of lymph node dissection (LND) in the management of renal cell carcinoma (RCC) has been controversial, with conflicting data regarding its oncologic benefit. Proponents of LND have suggested that it may benefit patients at increased risk of lymph node (LN) metastases, which prior studies may have been underpowered to detect. We therefore utilized a large, multiinstitutional cohort to evaluate the association of LND with survival among patients undergoing RN for RCC.
METHODS: We identified 2,722 patients who underwent RN for M0 RCC between 1990 and 2010 at Mayo Clinic and San Raffaele Scientific Institute, including 1,215 (45%) with concomitant LND. A propensity score (PS) for receipt of LND was constructed using clinicopathologic features. The associations of LND with development of distant metastases, cancer-specific mortality (CSM), and all-cause mortality (ACM) were evaluated using Cox regression models adjusted for PS quintile or stabilized inverse probability weights (IPW). Internally predicted probabilities for pN1 disease were estimated using logistic regression.
RESULTS: Overall, 171 (6.3%) patients were pN1. There were no statistically significant differences in clinicopathologic features stratified by LND after PS adjustment. Median follow-up among survivors was 9.6 years, during which time 787 patients developed distant metastases and 622 died from RCC. Overall, LND was not significantly associated with a reduced risk of distant metastases, CSM, or ACM using any of the PS techniques (Table) . More importantly, we examined the association of LND with oncologic outcomes among patients at increased risk of pN1 disease. Here, LND was not associated with oncologic outcomes among patients with preoperative radiographic lymphadenopathy (cN1), and no consistent association with improved oncologic outcomes was noted across increasing probability thresholds for pN1 disease from 0.10 to 0.50. CONCLUSIONS: The current analysis of a large, international cohort indicates that LND is not associated with improved oncologic outcomes among patients undergoing RN for M0 RCC, including patients at increased risk of LN metastases such as those with radiographic lymphadenopathy (cN1) or across increasing probability thresholds for pN1 disease.
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ASSESSMENT OF METASTASECTOMY COMPLICATIONS IN RENAL CELL CARCINOMA INTRODUCTION AND OBJECTIVES: Metastasectomy (MSx) is a viable option in patients with metastatic renal cell carcinoma (mRCC). Available information on perioperative outcomes is scarce. We assess complications of MSx in a large population-based US cohort.
METHODS: The Nationwide Inpatient Sample (2000-2011) was utilized to abstract all patients with a primary diagnosis of mRCC. MSx was defined as an organ-specific resection as a diagnosis of a metastasis to a corresponding site (liver; lung; brain; bones; lymph nodes; adrenal) during the same admission. All procedures concomitantly performed with radical or partial nephrectomies were excluded. Baseline characteristics and multivariable logistic regression analyzes described in-hospital complications, length of stay, and mortality following MSx.
RESULTS: Overall, 26990 weighted patients had mRCC. Of those, 949 were treated with a MSx (3.5%). Common sites of MSx were liver (47.8%) and lung (33.2%). MSx patients were significantly younger than non-MSx patients (60 vs. 62 years, p¼0.013). Overall in-hospital mortality rate was 2%. The most common in-hospital complications were prolonged length of stay, defined as ¼7 days (38.5%), respiratory complications (17.1%), vascular complications (14.8%), and blood transfusions (16.3%). In multivariable analyses neither patient nor hospital characteristics were significant predictors of overall complication rates.
CONCLUSIONS: This study suggests that MSx is a sensible and safe approach for the treatment of mRCC. We did not find significant predictors of complications for MSx in mRCC patients. Nevertheless, postoperative care should be optimized to prevent unnecessary complications and prolonged length of stay. METHODS: Patients were enrolled following a choice of primary intervention or active surveillance (AS). Patients who received intervention were further defined by the type of treatment: partial nephrectomy (PN), radical nephrectomy (RN), or ablation. Cancer-specific and overall survival rates were estimated with the Kaplan-Meier method and compared using the log-rank test. Glomerular filtration rate (GFR) was compared across groups at enrollment, 3, 6, and 12 months, and last available measurement. The Short Form 12 (SF-12) questionnaire was administered at enrollment, 6 and 12 months, and every year thereafter. The Physical Component Summary (PCS) and Mental Component Summary (MCS) of the SF-12 were evaluated among groups and over time using ANOVA and linear regression mixed modeling.
RESULTS: Of the 615 enrolled patients, 317 originally chose AS. A total of 256 patients underwent PN, 47 RN, and 36 ablation. PN patients were younger (P < 0.001) and had fewer comorbidities (P < 0.001) than AS patients. Cancer-specific survival at 7 years did not Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e737
